TLDR: Firefly Bio has emerged from stealth mode with $94 million in funding co-led by Versant Ventures and MPM BioImpact. The company has assembled an “ADC dream team” to work on developing degrader-antibody conjugates (DACs), a new class of therapies to fight cancer. The team, led by CEO Scott Hirsch, includes scientists with backgrounds at Genentech, Merck & Co., and AbbVie, as well as Nobel laureate Carolyn Bertozzi. Firefly’s platform focuses on protein degraders, which use the cell’s natural degradation machinery to eliminate disease-causing proteins. The company aims to deliver a more selective payload that can improve the therapeutic index and clinical outcomes for patients.
Igniting Potential: $94M Funds Firefly Bio’s Protein Breakthrough with ADC Dream Team
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a